MARKET

SLP

SLP

Simulations Plus Inc
NASDAQ
45.70
-0.82
-1.76%
After Hours: 45.70 0 0.00% 16:02 04/15 EDT
OPEN
46.68
PREV CLOSE
46.52
HIGH
46.82
LOW
45.51
VOLUME
79.38K
TURNOVER
0
52 WEEK HIGH
52.69
52 WEEK LOW
32.64
MARKET CAP
913.31M
P/E (TTM)
88.33
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SLP last week (0408-0412)?
Weekly Report · 21h ago
YieldBoost Simulations Plus From 0.5% To 16.1% Using Options
NASDAQ · 6d ago
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
NASDAQ · 04/08 13:06
Weekly Report: what happened at SLP last week (0401-0405)?
Weekly Report · 04/08 09:21
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket
Reliance Global Group, Inc. Shares fell sharply in today’s pre-market trading after reporting financial results for the year ended Dec 31, 2023. The company posted a net loss of $12.0 million for 2023, compared to net income of $6.5 million in 2022. Gainers MediaCo Holding Inc. Rose 175% to $3.85 in pre- market trading.
Benzinga · 04/05 09:45
Health Care Sector Update for 04/04/2024: FNA, SLP, ADCT, ALUR
NASDAQ · 04/04 20:03
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. The company issued strong preliminary first-quarter net sales guidance. TC Biopharm (Holdings) Plc shares climbed 130.1% in the mid-day session.
Benzinga · 04/04 17:21
Simulations Plus stock jumps 25% amid FDA renewal, earnings report
Simulations Plus stock jumps 25% amid FDA renewal, earnings report. The company announced the FDA had renewed its license to the DILIsym toxicology software platform for the seventh year. Simulations Plus reported fiscal Q2 revenue rose 18% year-over-year to $18.3M.
Seeking Alpha · 04/04 16:19
More
About SLP
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.

Webull offers Simulations Plus Inc stock information, including NASDAQ: SLP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLP stock methods without spending real money on the virtual paper trading platform.